ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,555.80
0.19%
S&P ASX All Technology
4,107.60
0.90%
Brent Oil
74.39
0.00%
US Dollar vs AUD
1.57356
0.00%
Bitcoin
97,116.74
-0.49%
Pepperstone
Advertisement
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Caribou Biosciences Inc (CRBU) Share Price

Caribou Biosciences Inc

Caribou Biosciences Inc (CRBU)

Amd Commo Exagr
1.35
0.04
(3.05%)
Closed 16 February 8:00AM
Delayed by 15 minutes
1.35
0.00
(0.00%)
After Hours: 11:57AM
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
1.35
Bid
1.34
Offer
1.35
Volume
1,184,810
1.32 Day's Range 1.4195
1.22 52 Week Range 8.33
Market Cap
122.246M
Previous Close
1.31
Open
1.35
Last Trade
450
@
1.35
(formt)
Last Trade Time
Financial Volume
US$ 1,610,234
VWAP
1.3591
Average Volume (3m)
1,444,546
Shares Outstanding
90,552,687
Dividend Yield
-
PE Ratio
-1.19
Earnings Per Share (EPS)
-1.13
Revenue
34.48M
Net Profit
-102.07M

About Caribou Biosciences Inc

Caribou Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. Caribou Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies.

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.cariboubio.com
Headquarters
Dover, Delaware, USA
Founded
-
Caribou Biosciences Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker CRBU. The last closing price for Caribou Biosciences was US$1.31. Over the last year, Caribou Biosciences shares have traded in a share price range of US$ 1.22 to US$ 8.33.

Caribou Biosciences currently has 90,552,687 shares in issue. The market capitalisation of Caribou Biosciences is US$118.62 million. Caribou Biosciences has a price to earnings ratio (PE ratio) of -1.19.

Ask ADVFN Intelligence (AI)

CRBU Latest News

More News

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
31 January 2025
CRBU (3.05%)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.05-3.571428571431.41.4151.228813431.29517297CS
4-0.23-14.55696202531.581.581.2213153561.40027016CS
12-0.5935-30.5376897351.94352.511.2214445461.72230245CS
26-0.5-27.0270270271.852.99951.2212698451.92128487CS
52-5.29-79.66867469886.648.331.2216533972.82704814CS
156-9.45-87.510.813.191.2213460885.01697672CS
260-16.3-92.351274787517.6532.6451.2212346406.26792679CS

CRBU - Frequently Asked Questions (FAQ)

What is the current Caribou Biosciences share price?
The current share price of Caribou Biosciences is US$ 1.35
How many Caribou Biosciences shares are in issue?
Caribou Biosciences has 90,552,687 shares in issue
What is the market cap of Caribou Biosciences?
The market capitalisation of Caribou Biosciences is USD 118.62M
What is the 1 year trading range for Caribou Biosciences share price?
Caribou Biosciences has traded in the range of US$ 1.22 to US$ 8.33 during the past year
What is the PE ratio of Caribou Biosciences?
The price to earnings ratio of Caribou Biosciences is -1.19
What is the cash to sales ratio of Caribou Biosciences?
The cash to sales ratio of Caribou Biosciences is 3.52
What is the reporting currency for Caribou Biosciences?
Caribou Biosciences reports financial results in USD
What is the latest annual turnover for Caribou Biosciences?
The latest annual turnover of Caribou Biosciences is USD 34.48M
What is the latest annual profit for Caribou Biosciences?
The latest annual profit of Caribou Biosciences is USD -102.07M
What is the registered address of Caribou Biosciences?
The registered address for Caribou Biosciences is 3500 S DUPONT HWY, KENT, DOVER, DELAWARE, 19901
What is the Caribou Biosciences website address?
The website address for Caribou Biosciences is www.cariboubio.com
Which industry sector does Caribou Biosciences operate in?
Caribou Biosciences operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
JTAIJet AI Inc
US$ 6.02
(133.33%)
104.48M
SRMSRM Entertainment Inc
US$ 0.6999
(95.50%)
254.39M
WRDWeRide Inc
US$ 31.4877
(83.39%)
21.07M
INLFINLIF Limited
US$ 16.27
(80.58%)
7.68M
MBRXMoleculin Biotech Inc
US$ 2.1201
(66.94%)
136.66M
BLACBellevue Life Sciences Acquisition Corporation
US$ 3.08
(-56.31%)
430.77k
BLACUBellevue Life Sciences Acquisition Corporation
US$ 3.36
(-52.68%)
5.21k
CSAICloudastructure Inc
US$ 19.0001
(-49.58%)
1.03M
NEXNNexxen International Ltd
US$ 10.30
(-49.16%)
164.82k
BSLKBolt Projects Holdings Inc
US$ 0.6626
(-46.13%)
13.4M
CNSPCNS Pharmaceuticals Inc
US$ 0.1415
(31.26%)
489.28M
MGOLMGO Global Inc
US$ 0.7176
(-15.08%)
417.31M
SRMSRM Entertainment Inc
US$ 0.6999
(95.50%)
254.39M
INTCIntel Corporation
US$ 23.60
(-2.20%)
230.26M
NVDANVIDIA Corporation
US$ 138.85
(2.63%)
194.99M

CRBU Discussion

View Posts
theorysuit theorysuit 3 weeks ago
What do you think of their shift to partial HLA matching?
👍️0
Monksdream Monksdream 1 month ago
CRBU. Under $2
👍️0
Monksdream Monksdream 2 months ago
CRBU under $2
👍️0
TrendTrade2016 TrendTrade2016 3 months ago
CRBU READY TO BEAST
👍️0
TrendTrade2016 TrendTrade2016 4 months ago
CRBU...NEW SCAN JUST GAVE ME THIS BIO
👍️0
Monksdream Monksdream 4 months ago
CRBU under $3
👍️0
Monksdream Monksdream 4 months ago
CRBU under $2
👍️0
Monksdream Monksdream 6 months ago
CRBU under $3
👍️0
Monksdream Monksdream 7 months ago
CRBU under $3
👍️0
jondoeuk jondoeuk 7 months ago
Earlier this year development of the lead CAR-NK programme, CB-020, was stopped, and now they are out of CAR-NK altogether. They disclosed it in an SEC filing and outlined a 12% workforce reduction https://www.sec.gov/Archives/edgar/data/1619856/000161985624000054/crbu-20240716.htm

This should extend their cash runway by at least six months, into the second half of 2026.
👍️0
Monksdream Monksdream 7 months ago
CRBU under $3
👍️0
Monksdream Monksdream 8 months ago
CRBU new 52 week low
👍️0
Monksdream Monksdream 8 months ago
CRBU new 52 week low
👍️0
NY1972 NY1972 8 months ago
Without engaging macrophage long term, CART and other ACT will have persistence issue as regulatory lymphocytes and TAM recoup. AFMD has the best approach with ICE engaging a few B CBNK cells for start and engaging endogenous NK and M in the maintenance phase
👍️0
Diego Rivas Diego Rivas 8 months ago
Any good news in here comming?
👍️0
jondoeuk jondoeuk 8 months ago
Among patients with four or more matching HLA alleles, mPFS was 14.4 months, versus 2.8 months in patients with three or fewer matches. But this is based on a retrospective analysis, so they will need to prove the theory prospectively. It was better in LBCL, with mPFS not reached, versus 2.8 months. Also, some improvement in the now-selected dose, 80 million CAR-T cells.
👍️0
jondoeuk jondoeuk 8 months ago
The BCMA-targeted space is already crowded enough and off-target toxicities, including agranulocytosis* could be a problem for its anti-CLL-1 CAR.

* CLL-1 is also highly expressed on almost all granulocytes and monocytes and on parts of myeloid progenitors in the normal bone marrow and peripheral blood.
👍️0
Monksdream Monksdream 8 months ago
CRBU new 52 week low
👍️0
stocksrising stocksrising 8 months ago
Yep, not a positive trend hence sub $3’s…fortunately other trials for varied indications could save company…
👍️0
jondoeuk jondoeuk 8 months ago
It gets worse. The updated (CB-010) data shows that the ORR (including CR rate) has fallen, so has the mDOR, the six-month PFS is poor and the pivotal trial has been delayed until H2 2025 following a new HLA partial matching strategy. The latter completely alters (in a bad way) the commercial strategy for an allo CAR-T product. They now need thirteen different off-the-shelf batches to be able to cater to ~90% of patients based on an ideal HLA match.
👍️ 1
Monksdream Monksdream 9 months ago
CRBU new 52 week low
👍️0
Monksdream Monksdream 9 months ago
CRBU new 52 week low
👍️0
Monksdream Monksdream 10 months ago
CRBU under $5
👍️0
stocksrising stocksrising 11 months ago
It seemed like they were running on all positive cylinders, but must have blown a gasket at current Conference/ Fireside???
👍️0
Monksdream Monksdream 1 year ago
CRBU new 52 week low
👍️0
jondoeuk jondoeuk 2 years ago
Yes, with both drugs still in development. As for CRBU, they gave an update (plus public offering) https://finance.yahoo.com/news/caribou-biosciences-reports-positive-clinical-200100822.html https://investor.cariboubio.com/static-files/d818ed1a-aea2-41c1-84ea-bd05a4276cbb

Personally, there seem to be red flags, such as no expansion/persistence data. I know they give huge amounts of LD chemo, higher (I think) than anyone else, which could be generating responses, explaining why there is no dose response.
👍️0
trueblue trueblue 2 years ago
.
👍️0
trueblue trueblue 2 years ago
$23.00 price target! Now that is a good start!! Glad I loaded up! Jmo
👍️0
NY1972 NY1972 2 years ago
Didn't they buy TRIL? Just gambling with billions from US government.
👍️0
jondoeuk jondoeuk 2 years ago
PFE is very selective in who they fund https://finance.yahoo.com/news/caribou-biosciences-announces-25-million-120000433.html
👍️0
trueblue trueblue 2 years ago
Great day in my accounts again! Really liking my CRBU shares! Jmo holding for the long haul!!
👍️0
Monksdream Monksdream 2 years ago
CRBU now No 9 on the Barchart Top 10
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
👍️0
trueblue trueblue 2 years ago
Added to my existing shares today, I bought shares months ago. I like Crbu a crisper company! Looks like Pfizer does also! Jmo
👍️0
Stockexpertpro Stockexpertpro 2 years ago
CRBU Loss 108 Million Dollars Company only has preclinical and phase 1 in its pipeline company is Years away from having anything if ever did a stock offering at 5.33$ for 25 Million thats only 1 QTR Cash burn for this company Sell the News https://www.cariboubio.com/pipeline/
👍️0
TheFinalCD TheFinalCD 2 years ago
CRBU= JUST WOW

https://finviz.com/quote.ashx?t=CRBU&ty=c&ta=1&p=d
👍️0
Monksdream Monksdream 2 years ago
CRBU No 1 on the early Barchart Top 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
👍️0

Your Recent History

NASDAQ
CRBU
Caribou Biosciences
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads